Yesterday, Alexion Pharmaceuticals (ALXN) came out with strong third quarter financials. The company reported earnings per share of 29 cents, well above the Zacks Consensus Estimate of 21 cents and 23 cents reported in the year-ago quarter. Revenues increased 34% to $102.6 million from $76.5 million in the corresponding period last year, driven by strong Soliris (eculizumab) sales. However, revenues increased 44% after excluding $5.3 million of Soliris sales from the third quarter of 2008 as they were associated with the previous quarter’s shipments. Soliris posted robust sales primarily due to the addition of a significant numbers of new patients in both the US and European countries. Soliris is Alexion’s only US Food and Drug Administration (FDA) approved (approval received in March 2007) product used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), a life threatening blood disorder. The drug had received European Commission (EC) approval ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT

**************************************************************

COV, Covidien plc

COV engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide. The company operates through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies.

COV said Wednesday it received Food and Drug Administration clearance for its new endotracheal tube, a device that helps patients breathe.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the

...

In my larval, pre-blogging days, I always faced the back-to-school moment with abject dread.  It meant returning to a program of the most severe, mind-numbing regimentation in the ghastly New York City public schools after a summer of idyllic unreality in the New Hampshire woods, where I went to a Lord of the Flies type of summer camp.  And so here I am, many decades later, still uneasy as the final page of the August calendar flies away in a hot Santa Ana wind, and a great hellfire closes in on the far eastern reaches of Los Angeles, and the American money system falls into a peculiar limbo, and every fifth person is out of work, or going bankrupt, or glugging down the seawater of default, or being denied coverage by health insurance that he-or-she has already shelled out ten grand for this year, or getting shot in

...

Headquartered in Woonsocket, Rhode Island, MultiCell Technologies, Inc. is an integrated biopharmaceutical company. Trading on the OTCBB, their commitment is to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technologies. The company plans to pursue strategic alliances to better penetrate the various markets for their therapeutics.

The company’s drug development program focuses on the modulation of the immune system. Their lead drug candidates include drugs to treat multiple sclerosis (MS)-related chronic fatigue, relapsing-remitting MS, type-1 diabetes, and infectious disease. MultiCell Technologies, Inc.’s therapeutic pipeline includes MCT-125, which is directed at treating chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients.

The company also has their MCT-175, a targeting relapse-remitting MS. MCT-175 targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. It is in preclinical

...

DrStockPick.com Stock Report!

Thursday August 20, 2009

**************************************************************

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Rhode Island on behalf of purchasers of the securities of Textron, Inc.  (NYSE: TXT) during the period between July 17, 2007 and January 29, 2009, inclusive (the “Class Period”).

Omniture, Inc. (NASDAQ: OMTR), a leading provider of online business optimization software, today announced the delivery of CMO Dashboards in collaboration with its extensive agency and technology partner ecosystem. Today, Omniture already delivers millions of dashboards and alerts to more than 5,000 customers every month. With CMO Dashboards, Omniture will

...

A couple of weeks ago I was in Fort McMurray, Alberta.  I was visiting two large oil sands operations, courtesy of Conoco Phillips (NYSE:COP), Syncrude Canada and the American Petroleum Institute, which sponsored the trip.  I’ve been all over the place, but never to a working oil sands operation.  This was a first for me, and quite an eye-opener.

What Are These Oil Sands?

Back in Pleistocene time, the glaciers covered much of northern Alberta.  In places, there was a mile of ice.  During some of the warmer periods, there was a lot of melting.  On occasion, and in some places, there were giant, glacial-dammed lakes.

Every now and again, these glacial dams would break, sending massive volumes of water downstream, wiping away pretty much everything along the way.  Well, it turns out that in this scoured-out area that included much of the rock covering some lower Cretaceous deposits of

...

We are presenting a list of companies which we believe are currently mispriced, based on our estimate of fair value, by the market. We develop our fair value ranges by projected free cash flow out one year and estimating an appropriate FCF multiple based on our assessment of risk and the strength of the balance sheet.

Cisco Systems [CSCO: 19.57, +0.84 (+4.48%)] Recent Price $17.04 Value Range 21.86 – $38.41 Cisco Systems, Inc. designs, manufactures and sells Internet protocol (IP)-based networking and other products related to the communications and information technology (IT) industry, and provides services associated with these products and their use. The Company provides a line of products for transporting data, voice, and video within buildings, across campuses, and around the world. Its products are designed to transform how people connect, communicate and collaborate. Cisco Systems, Inc.’s products, which include primarily routers, switches, and products that the

...

div style="text-align: justify;"Barclays is out with an interesting call on span style="font-weight: bold;"Hess Corp. (NYSE:HES)/span upgrading the shares to Overweight from Equal weight and maintaining their $75 price target.br /br /According to the analyst the upgrade comes following recent sharp underperformance. As one of the most oil-levered producers within their research universe, they believe Hess is well positioned to benefit from a rising oil price environment while offering a significant exploration potential upside with no sizable upfront premium.br /br /Firm notes that although they have long been intrigued by the company’s vast long-term resource potential in Brazil, Ghana, Libya, and Australia, they were uncomfortable about the shares’ valuation. They believed the market had prematurely awarded too much premium for its exploration potential and ignored the unavoidable underlying risks associated with such a concentrated high-interest/high-impact drilling program span style="font-weight: bold;"(dry hole is the norm, not the exception, in the Eamp;P business. ...

Today is the end of the 2009 fiscal year, and many states are still scrambling to get budgets in place for the 2010 fiscal year. It is not easy since when the economy turns south, so do tax revenues, and states are not allowed to run deficits or borrow for operating needs. Some states have managed to cut costs or raise taxes enough to close their deficits for the upcoming year. The only two states without a budget problem are Montana and North Dakota. As shown in the table below (from http://www.cbpp.org/cms/index.cfm?fa=view&id=711), the total spending cuts or revenue increase needs to be $166 billion or 24% of the projected budget. To some extent states have used "rainy day funds" and the money from the Federal Stimulus bill to close some of the gap. Still the problem is very severe with 5 states (CA, AZ,

...

[Editor’s Note: Is it a new bull market, or just a bear-market rally that’s going to separate investors from the last of their cash? For the shrewdest investors, it may not matter. A new offerfrom Money Morning is a two-way win for investors: Noted commentator Peter D. Schiff’s new book – “Little Book of Bull Moves in a Bear Market” – shows investors how to profit no matter which way the market moves, while our monthly newsletter, The Money Map Report, provides ongoing analysis of the global financial markets and some of the best profit plays you’ll find anywhere – including such markets as Taiwan and China. To find out how to get both, check out our newest offer.

To read a related story on how the long-term dismantling of U.S. banking regulations set the stage for the …